Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MDxHealthMDXH -1.52%49 5-Year Yield-on-Cost % is 0.00 as of Jul. 23, 2026. GuruFocus rates MDXH with a GF Score™ of 49/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, MDxHealth ranks worse than 1562498.44% on this metric.
MDxHealth's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for MDxHealth's 5-Year Yield-on-Cost % or its related term are showing as below:
MDXH's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.52 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
MDxHealth 5-Year Yield-on-Cost % Related Terms
MDXH vs AWHL, BIOQ, XWEL: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, MDxHealth's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MDxHealth 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where MDxHealth's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of MDxHealth is calculated as
MDxHealth (MDXH) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on MDxHealth and its competitors. According to the industry distribution chart, MDxHealth ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry.
Is MDxHealth's 5-Year Yield-on-Cost % too high?
MDxHealth's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, MDxHealth ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, MDxHealth has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's 5-Year Yield-on-Cost % compare to AWHL and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, MDxHealth ranks #999999 out of 64 companies for 5-Year Yield-on-Cost %. This places MDxHealth in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.52, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on MDxHealth and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MDxHealth's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (MDXH) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.43 — trading 80.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. MDxHealth's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For MDxHealth (MDXH), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MDxHealth (MDXH) Overvalued in 2026?
Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued.
The current stock price of $0.43 is trading 80.4% below its estimated GF Value™ of $2.20.
GuruFocus considers MDxHealth to be Possible Value Trap.
Key valuation signals for MDXH:
5-Year Yield-on-Cost %: 0.00
GF Value™: $2.20 vs. price of $0.43 (80.4% below fair value)
No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
49GF Score
Get the complete analysis for MDXH
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXH has been successfully added to your 
